Kilitch Drugs (India)'s Q1 FY 2025-26 Quarterly Results

Result Summary

• Kilitch Drugs (India) Ltd reported a 0.9% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 26.8%.
• Its expenses for the quarter were up by 5.7% QoQ and 22.9% YoY.
• The net profit decreased 38.3% QoQ and increased 1963.6% YoY.
• The earnings per share (EPS) of Kilitch Drugs (India) Ltd stood at 1.9 during Q1 FY 2025-26.

Financial Statments for Q1 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Kilitch Drugs (India) Ltd is a pharmaceutical company primarily engaged in the manufacture and distribution of drug formulations and pharmaceutical products. The company operates within the healthcare and pharmaceutical industry, focusing on providing a range of medicines and health solutions. Kilitch Drugs is known for its production capabilities in the formulation of various medications, catering to both domestic and international markets. The company may have undergone recent developments that are not specified here, but it continues to maintain a presence in the healthcare sector with its array of pharmaceutical offerings.

Revenue

For the first quarter of fiscal year 2026 (Q1FY26), Kilitch Drugs reported a total income of ₹45.70 crores. This represents a quarter-over-quarter (QoQ) increase of 0.9% from ₹45.29 crores in the fourth quarter of fiscal year 2025 (Q4FY25). Compared to the first quarter of fiscal year 2025 (Q1FY25), the company experienced a year-over-year (YoY) growth of 26.8% from ₹36.03 crores. The steady increase in total income suggests a growth trajectory in the company's revenue generation capabilities over the year.

Profitability

In terms of profitability, Kilitch Drugs recorded a profit before tax of ₹3.45 crores in Q1FY26, which marks a significant decline of 34.9% from the previous quarter's profit of ₹5.30 crores in Q4FY25. However, the profit before tax saw a substantial YoY increase of 109.1% from ₹1.65 crores in Q1FY25. The tax expense for Q1FY26 was ₹1.19 crores, which decreased by 26.5% QoQ from ₹1.62 crores in Q4FY25 and by 22.7% YoY from ₹1.54 crores in Q1FY25. The profit after tax for Q1FY26 amounted to ₹2.27 crores, reflecting a 38.3% QoQ decrease from ₹3.68 crores in Q4FY25 but a remarkable 1963.6% YoY increase from ₹0.11 crores in Q1FY25. Earnings per share for the quarter stood at ₹1.90, down 13.6% QoQ from ₹2.20 in Q4FY25 and up 137.5% YoY from ₹0.80 in Q1FY25.

Operating Metrics

Kilitch Drugs' total expenses for Q1FY26 were reported at ₹42.25 crores, showing a 5.7% increase QoQ from ₹39.99 crores in Q4FY25, and a 22.9% increase YoY from ₹34.37 crores in Q1FY25. This increase in expenses could be attributed to various operational factors impacting the company during the quarter. The company's financial performance indicates fluctuations in profitability metrics, likely influenced by changes in income and expenses. The variations in tax expenses and earnings per share further highlight the dynamic nature of the company's financial operations over the reviewed periods.